<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749216</url>
  </required_header>
  <id_info>
    <org_study_id>12025</org_study_id>
    <secondary_id>H8A-JE-LZAK</secondary_id>
    <nct_id>NCT00749216</nct_id>
  </id_info>
  <brief_title>Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease</brief_title>
  <official_title>Multiple-Dose Safety in Japanese Subjects With Mild-to-Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK)
      and pharmacodynamics (PD) of multiple dosing Solanezumab in subjects with mild-to-moderate AD
      in Japanese population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the extended ADAS-Cog stand for Alzheimer's Disease Assessment Scale-Cognitive subscale</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic of Aβ1-40 and Aβ1-42</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>QW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of 400mg once each week for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of 400mg once every four weeks for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Q8W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of 400mg once every eight weeks for 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solanezumab</intervention_name>
    <arm_group_label>QW</arm_group_label>
    <arm_group_label>Q4W</arm_group_label>
    <arm_group_label>Q8W</arm_group_label>
    <other_name>LY2062430</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or non-fertile women, at least 50 years of age.(Women who are not surgically
             sterilized must be post-menopausal for at least 1 year.)

          -  Patients with mild to moderate AD by following disease diagnostic criteria

               -  National Institute of Neurological and Communicative Disorders and
                  Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA)
                  criteria

               -  Modified Hachinski Ischemia Scale score of ≦ 4

               -  Folstein Mini-Mental State Examination (MMSE) score of 15 through 26

               -  Geriatric Depression Scale (GDS) score of ≦ 10 on the staff-administered short
                  form

        Exclusion Criteria:

          -  Patients who don't have a reliable caregiver who is in frequent contact with the
             patient, who will accompany the patient to the office and/or be available by telephone
             at designated times, and will monitor administration of prescribed medications.

          -  Patients who have an MRI or CT scan since the onset of symptoms of AD that is
             inconsistent with a diagnosis of AD.

          -  Patients who have received acetylcholinesterase inhibitors (AChEIs) or memantine for
             less than 4 months, or have less than 2 months of stable therapy on these treatments.

          -  Patients who have current serious or unstable illnesses including hepatic, renal,
             gastroenterologic, respiratory, cardiovascular (including ischemic heart disease),
             endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic
             disease and other conditions that, in the investigator or subinvestigator(s)'s
             opinion, could interfere with the analyses of safety and efficacy in this study.

          -  Patients who have a history within the last 5 years of a serious infectious disease
             affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head
             trauma resulting in protracted loss of consciousness within the last 5 years, or
             multiple episodes of head trauma.

          -  Patients who have a history within the last 5 years of a primary or recurrent
             malignant disease with the exception of resected cutaneous squamous cell carcinoma in
             situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer
             with a normal PSA post-resection.

          -  Patients who have allergies to humanized monoclonal antibodies.

          -  Patients who have a history within the last 5 years of a primary or recurrent
             malignant disease with the exception of resected cutaneous squamous cell carcinoma in
             situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer
             with a normal PSA post-resection.

          -  Patients who have ECG abnormalities obtained that, in the opinion of the investigator,
             are clinically significant with regard to the subject's participation in the study,
             including QTc prolongation (Bazett's corrected QTc interval, QTcB; males &gt;435 msec or
             females &gt;455 msec) or abnormally wide QRS complexes (resulting from bundle-branch
             blocks, interventricular conduction delays, or pacemakers).

          -  Patients who have a current, required use or expected use of excluded drugs through
             the duration(These drugs include typical neuroleptics (antipsychotics). In addition,
             typical neuroleptics may not be taken within 4 weeks.

          -  Patients who are currently taking chronic medications that affect central nervous
             system (CNS) function, and are not dose-stabilized for at least 4 weeks.

          -  Patients who have a ventriculoperitoneal shunt or gamma globulin (IgG) therapy within
             the last year.

          -  Patients who have previously completed or withdrawn from this study or previous
             participation in any other study investigating active immunization against Aβ.

          -  Patients who have any contraindications for MRI studies, including claustrophobia, the
             presence of metal (ferromagnetic) implants, or cardiac pacemaker.

          -  Patients who weigh less than 40 kg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ehime</city>
        <zip>791-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hiroshima</city>
        <zip>728-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>672-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyoto</city>
        <zip>616-8255</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <disposition_first_submitted>May 27, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>May 27, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 2, 2010</disposition_first_posted>
  <last_update_submitted>May 27, 2010</last_update_submitted>
  <last_update_submitted_qc>May 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

